Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof

A skeleton compound, anti-tumor effect technology, applied in anti-tumor drugs, steroids, organic chemistry, etc., to achieve the effect of reducing production costs, high economy, and inhibiting lung metastasis

Active Publication Date: 2019-07-19
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have shown that the cyclopentane polyhydrophenanthrene skeleton compound diosgenin and its derivatives can play an anti-hepatic effect by regulating the level of FVIII in vivo
[0003] However, there is no research so far from the perspective of the blood coagulation system. Studies have shown that a cyclopentane polyhydrophenanthrene skeleton compound can play an anti-hepatic effect by regulating FVIII factors. This study is the first to systematically evaluate cyclopentane polyhydrophenanthrene in vitro and in vivo The effect and mechanism of the skeleton compound on the proliferation and migration of liver cancer cells mediated by blood coagulation factor FVIII, providing new research directions and data support for the diagnosis, treatment and drug development of liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof
  • Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof
  • Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] In this example, 3-acetylfurostane ester compounds were synthesized, specifically compounds 4-7 were synthesized.

[0043] 1. Synthesis of compound 4: 3-acetyl-aspirin furostanyl ester

[0044] Compound 3 (459mg, 1mmol), aspirin (216mg, 1.2mmol) and 4-dimethylaminopyridine (DMAP, 24mg, 0.2mmol) were dissolved in anhydrous dichloromethane (30mL) and stirred for 10min to form solution A. 1-Ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl, 383mg, 2mmol) was dissolved in 8mL of anhydrous dichloromethane to form solution B, at room temperature Solution B was slowly added dropwise to solution A, and the temperature was gradually raised to 35-40°C for about 8 hours. The reaction progress was detected by TCL, and the reaction was basically complete. The resulting reaction solution was washed successively with 5% sodium chloride solution, saturated sodium bicarbonate solution and 5% sodium chloride solution, the organic phase was separated and dried with anhydr...

Embodiment 2

[0056] In this example, furostane diester compounds were synthesized, specifically including compounds 9-12.

[0057] 1. Synthesis of compound 9: aspirin furostane diester

[0058] Compound 8 (416mg, 1mmol), aspirin (432mg, 2.4mmol) and DMAP (48mg, 0.4mmol) were dissolved in anhydrous dichloromethane (30mL) and stirred for 10min to form solution A, EDC.HCl (766mg, 4mmol ) was dissolved in 8 mL of anhydrous dichloromethane to form solution B, and solution A was slowly added dropwise to solution B at room temperature, and the temperature was gradually raised to 35-40°C for about 8 hours. The reaction progress was detected by TCL, and the reaction was basically complete. The resulting reaction solution was washed successively with 5% sodium chloride solution, saturated sodium bicarbonate solution and 5% sodium chloride solution, the organic phase was separated and dried with anhydrous sodium sulfate, and then washed with petroleum ether:ethyl acetate=10:1( v / v) As an eluent, it ...

Embodiment 3

[0070] In this example, spirostanoid ester compounds were synthesized, specifically including compounds 13-16.

[0071] 1. Synthesis of compound 13: aspirin spirostanyl ester

[0072] Compound 1 (414mg, 1mmol), aspirin (216mg, 1.2mmol) and DMAP (24mg, 0.2mmol) were dissolved in anhydrous dichloromethane (30mL) and stirred for 10min to form solution A, EDC.HCl (383mg, 2mmol ) was dissolved in 5 mL of anhydrous dichloromethane to form solution B, and solution B was slowly added dropwise to solution A at room temperature, and the temperature was gradually raised to 35-40°C for about 8 hours. The reaction progress was detected by TCL, and the reaction was basically complete. The resulting reaction solution was washed successively with 5% sodium chloride solution, saturated sodium bicarbonate solution, and 5% sodium chloride solution, and the organic phase was separated and dried with anhydrous sodium sulfate, and then washed with petroleum ether:ethyl acetate=10:1( v / v) used as e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling the blood coagulation factor VIII level to play an anti-tumor role, and application of the cyclopentanopolyhydrophenanthrene skeleton compound to preparation of drugs for treating blood coagulation factor VIII-mediated tumors, in particular to drugs for treating a blood coagulation factor VIII-mediated tumor which is blood coagulation factor VIII-mediated liver cancer. Experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit expression and secretion of HUVEC endothelial cells FVIII, inhibit HUVEC endothelial cell FVIII mediated hepatoma carcinoma cell proliferation, and inhibit adhesion of tumor cells and platelets mediated by FVIII secreted by HUVEC cells, and in-vivo experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit lung metastasis of liver cancer by inhibiting the level of FVIII.

Description

technical field [0001] The invention belongs to the field of medicines, and relates to a cyclopentane polyhydrophenanthrene skeleton compound capable of regulating the level of blood coagulation factor VIII to exert an antitumor effect and its application. Background technique [0002] Traditional anti-tumor drugs mainly achieve anti-tumor effects by directly killing and injuring cancer cells, with many side effects, and most drugs cannot improve the abnormal function of the blood coagulation system caused by tumors. Studies have shown that the cyclopentane polyhydrophenanthrene skeleton compound dioscin and its derivatives can play the role of anti-venous and arterial thrombosis by regulating the level of coagulation factor VIII (FVIII) in the body, and also found that dioscin and its derivatives have Direct antitumor activity. However, no studies have shown that the cyclopentane polyhydrophenanthrene skeleton compound diosgenin and its derivatives can play an anti-hepatic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J71/00A61P35/00A61P35/04
CPCA61P35/00A61P35/04C07J71/0005
Inventor 黄文李幼平余睽张俊华辛光钮海张伯礼
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com